MACITENTAN (macitentan) by Aurobindo Pharma is endothelin receptor antagonists [moa]. First approved in 2024.
Drug data last refreshed 20h ago
Endothelin Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
A Study of Macitentan, in Healthy Japanese Male Participants
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
Worked on MACITENTAN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.